Navigation Links
FDA Accepts Takeda and Lundbeck's Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
Date:12/12/2012

ine and histamine in specific areas of the brain.

Across the doses of 5-20 mg, the most commonly observed adverse reactions in MDD patients treated with vortioxetine in placebo-controlled studies (incidence greater than or equal to 5% and at least twice the rate of placebo) were: nausea, constipation and vomiting.  Overall, 6.5% of the patients who received vortioxetine discontinued treatment due to an adverse reaction, compared with 3.8% of placebo-treated patients in these studies. Nausea was the most common adverse reaction reported as a reason for discontinuation and considered to be drug-related.

Takeda and Lundbeck alliance
In September 2007, Lundbeck and Takeda formed a strategic alliance for the exclusive co-development and co-commercialization in the United States and Japan of several compounds in Lundbeck's pipeline for mood and anxiety disorders. The partnership initially focuses on co-development and co-commercialization of the two most advanced compounds in Lundbeck's pipeline for mood and anxiety disorders, vortioxetine and tedatioxetine (Lu AA24530). If approved, the companies plan to co-promote the products in the United States and Japan.

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck's U.S. business is based in Deerfield, Illinois. To learn more about Lundbeck in the U.S., visit www.lundbeckus.com.

L
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.; H. Lundbeck A/S
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
2. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
3. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
4. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
5. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
6. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
7. Call for Submissions: ICAP Patent Brokerage Announces Expansion of Life Sciences Practice and Increased Buyer Interest in Related Intellectual Property
8. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
9. Medical Marijuana, Inc. Portfolio Company PhytoSPHERE Systems, LLC Cites Broad Applications of its 2013 Harvest of Uniquely Valuable Hemp Oil
10. Lotus Pharmaceutical Company Inc. Filed Its Abbreviated New Drug Application (ANDA) Containing a Paragraph IV Certification for a Generic Version of Xenical(R) with the U.S. Food & Drug Administration (FDA)
11. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... -- Levi & Korsinsky announces that a class action ... Court for the District of Nevada ... Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities between ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt . ... the Company violated federal securities laws by issuing false ...
(Date:8/28/2014)... 2014 According to a new ... (RFID) Market (Tags, Readers, Middleware, Printers and Cabinets) - ... 2014 - 2020" the global radiofrequency identification (RFID) market ... is expected to grow at a CAGR of 13.9% ... of USD 5.3 billion in 2020. Browse ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Multiforme Therapeutics in Asia-Pacific Markets to ... High Unmet Need in Newly Diagnosed ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... HERZELIYA, Israel, September 30 ... in an investment round led by 7 Health,Ventures. ... in the round as well. , ... optical guidance systems used,in Computer Tomography (CT), fluoroscopy ...
... Ill., Sept. 30 Life Spine announced today that ... 510(k) marketing approval to the SENTINEL Occipito-Cervico-Thoracic (OCT) System. ... and promotes fusion from the occiput to thoracic spine, ... procedures. Polyaxial screws are available in multiple diameters and ...
Cached Medicine Technology:
(Date:8/28/2014)... 29, 2014 AltMed , ... industry precision to the development and production of ... its primary location in Sarasota County. , ... a total commitment to attracting new industry and ... says David Wright, President and CEO of AltMed. ...
(Date:8/28/2014)... When David Gergen, President of Pro Player ... was asked to publicly support Mr. Brnovich in his ... seat in the State of Arizona, Mr. Gergen could ... Hall of Fame wide receiver Roy Green in addition ... Green, Kennard and Walczak are members of Pro Player ...
(Date:8/28/2014)... New Energy Works Timberframe plans for a ... country to Log & Timber Home Shows starting in ... Energy Works team will invite the shows’ attendees into ... expertise, project images, and their new 2015 project calendar. ... Mid-West Representative, will present “A fun-fill odyssey: Realizing your ...
(Date:8/28/2014)... 42-year-old investment banker arrives at the emergency department ... He drinks alcohol every dayoften at business lunches, ... health, he decided to quit drinking and had ... emergency. , It,s a common scenario in emergency ... alcohol consumption and develops withdrawal. , Withdrawal is ...
(Date:8/28/2014)... 28, 2014 On August 21, the ... its 2013 Annual Report, featuring the organization’s audited financial ... , According to the report, in 2013, the ... programs versus 14 cents on fundraising and administration. ... a minimum,” wrote the Foundation’s chief executive officer, Melinda ...
Breaking Medicine News(10 mins):Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 2Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3Health News:Mesothelioma Applied Research Foundation’s Annual Report 2013 Release 2
... 2008) -- Pancreatic cancer is one of the ... in a major step forward, researchers at NewYork-Presbyterian ... radiation therapy prior to surgery nearly doubles survival ... "Patients who received pre-surgical (neoadjuvant) radiation had almost ...
... unmatched in its ability to deliver a ... across clinical settings to aid decision-making and ... announced that it earned two of Healthcare ... four of the five categories, ICA was ...
... Consumption and Kidney Cancer , There is no ... kidney cancer, according to a pooled analysis of prospective ... increasing worldwide, but the cause of the increase remains ... to an association between consumption of fat, protein, and ...
... , HARRISBURG, Pa., Nov. 25 In ... School District, the Pennsylvania Department of Health held vaccination clinics ... School on Nov. 19 and Nov. 24. , ... given to approximately 560 parents, students, and staff after an ...
... those with poor glucose control likely to have artery disease ... earlier research, a new study has identified a genetic ... in type 2 diabetes patients with poor sugar glucose (glycemic) ... on a genetic chromosome known as chromosome 9p21 are ...
... to blame, study concludes , , TUESDAY, Nov. 25 (HealthDay News) ... cancer for older women, according to a new study that ... their mammogram habits. , The weight itself is to blame ... who are above their healthy weight have higher levels of ...
Cached Medicine News:Health News:Radiation before surgery improves pancreatic cancer outcomes 2Health News:Radiation before surgery improves pancreatic cancer outcomes 3Health News: Informatics Corporation of America Takes 2008 Healthcare IT Summit by Storm, Winning Two of Five Award Categories 2Health News: Informatics Corporation of America Takes 2008 Healthcare IT Summit by Storm, Winning Two of Five Award Categories 3Health News:Also in the Nov. 25 JNCI 2Health News:Also in the Nov. 25 JNCI 3Health News:Also in the Nov. 25 JNCI 4Health News:Chromosome Linked to Diabetics' Heart Risks 2Health News:Weight Boosts Older Women's Breast Cancer Risk 2Health News:Weight Boosts Older Women's Breast Cancer Risk 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: